For patients with melanoma, socioeconomic disparities persist within insured populations, specifically those in nonintegrated health care systems.
Does lung cancer screening based on age and smoking status sufficiently predict lung cancer risk and prognosis, or are expanded screening criteria needed?
Researchers investigated patients’ colorectal cancer screening option preferences after the USPSTF lowered the screening age to 45 years.
Investigators sought to develop and validate the COVID-HEART predictor to determine risk for adverse events in patients hospitalized with COVID-19.
Although adverse events were more likely with mRNA-based COVID-19 vaccines, the benefits of mRNA vaccination exceeded the risks.
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
In all, 32 patients had a response, translating to an ORR of 66.7%.
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
